Summary
Background The health impacts of ambient air pollution impose large costs on society. While all people are exposed to air pollution, older individuals tend to be disproportionally affected. As a result, there is growing concern about the public health impacts of air pollution as many countries undergo rapid population ageing. We investigated the spatial and temporal variation in the health economic cost of deaths attributable to ambient air pollution, and its interaction with population ageing from 2000 to 2016 at global and regional levels.
Methods We developed an age-adjusted measure of the value of a statistical life year (VSLY) to estimate the health economic cost attributable to ambient PM2.5 pollution using the Global Burden of Disease 2017 data and country-level socioeconomic information. First, we estimated the global age- and cause-specific mortality and years of life lost (YLL) attributable to PM2.5 pollution using the global exposure mortality model (GEMM) and global estimates of exposure derived from ground monitoring, satellite retrievals and chemical transport model simulations at 0.1° × 0.1° (~11 km at the equator) resolution. Second, for each year between 2000 and 2016, we translated the YLL within each age-group into a health-related economic cost using a country-specific, age-adjusted measure of VSLY. Third, we decomposed the major driving factors that contributed to the temporal change in health costs related to PM2.5. Finally, we conducted a sensitivity test to analyze the variability of the estimated health costs to four alternative valuation measures. We identified the uncertainty intervals (UIs) from 1000 draws of the parameters and exposure-response functions by age, cause, country and year. All economic values are reported in 2011 purchasing-power-parity-adjusted US dollars.
Findings Globally, 8.42 million (95% UI: 6.50, 10.52) deaths and 163.68 million (116.03, 219.44) YLL were attributable to ambient PM2.5 in 2016. The average attributable mortality for the older population was 12 times higher than for those younger than 60 years old. In 2016, the global health economic cost of ambient PM2.5 pollution for the older population was US$2.40 trillion (1.89, 2.93) accounting for 59% of the cost for the total population. The health cost for the older population alone was equivalent to 2.1% (1.7%, 2.6%) of global gross domestic product (GDP) in 2016. While the economic cost per capita for the older population was US$2739 (2160, 3345) in 2016, the cost per capita for the younger population was only US$268 (205, 335). From 2000 to 2016, the annual global health economic cost for the total population increased from US$2.37 trillion (1.88, 2.87) to US$4.09 trillion (3.19, 5.05). Decomposing the factors that contributed to the rise in health economic costs, we found that increases in GDP per capita, population ageing, population growth, age-specific mortality reduction, and PM2.5 exposure changed the total health economic cost by 77%, 21.2%, 15.6%, -41.1% and -0.2%, respectively. Compared to using an age-invariant VSLY or an age-invariant value of a statistical life (VSL), the estimates of the older population’s share of the total health economic cost using an age-adjusted VSLY was 2 and 18 percentage points lower, respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Qiushi Foundation, and the Resnick Sustainability Institute at California Institute of Technology.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for access to the data should be made to the corresponding author at zhuliu{at}tsinghua.edu.cn. Data could be made available provided the applicant has appropriate ethics approval and approval from the authors.
